drugset
drugset / Trial / NCT06345482

A Study of MHB039A for Advanced Solid Tumor

NCT06345482 ↗

Phase 1/2 Active not recruiting 196 enrolled Minghui Pharmaceutical (Hangzhou) Ltd
NaSingle-groupOpen-labelTreatment

Summary

Phase I/II open label, multicenter study to evaluate the efficacy and safety of MHB039A in advanced malignant tumors.

Timeline

Start
2024-04-16
Primary completion
2028-04-01
Completion
2029-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject MHB039A Unknown 5 mg/kg Intravenous
Subject MHB039A Unknown 10 mg/kg Intravenous
Subject MHB039A Unknown 20 mg/kg Intravenous
Subject MHB039A Unknown 30 mg/kg Intravenous

Indications

neoplasm